var text = [{"boxId":"1","infoText":"Management of severe chronic primary mitral regurgitation","boxType":BoxTypes.ACTIVITY_STARTING_POINT,"nextBox":"2"},{"boxId":"2","infoText":"Symptoms","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"3"},{"text":"Yes","eventAction":"8"}]},{"boxId":"3","infoText":"LVEF ≤60% or LVESD ≥45 mm","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"4"},{"text":"Yes","eventAction":"7"}]},{"boxId":"4","infoText":"New onset of AF or SPAP &gt;50 mmHg","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"5"},{"text":"Yes","eventAction":"7"}]},{"boxId":"5","infoText":"High likelihood of durable repair, low surgical risk, and presence of risk factors<sup>a<\/sup>","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"6"},{"text":"Yes","eventAction":"7"}]},{"boxId":"6","infoText":"Follow-up","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"7","infoText":"Surgery (repair whenever possible)","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"8","infoText":"LVEF &gt;30%","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"9"},{"text":"Yes","eventAction":"7"}]},{"boxId":"9","infoText":"Refractory to medical therapy","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"10"},{"text":"Yes","eventAction":"11"}]},{"boxId":"10","infoText":"Medical therapy","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"11","infoText":"Durable valve repair is likely and low comorbidity","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"No","eventAction":"12"},{"text":"Yes","eventAction":"7"}]},{"boxId":"12","infoText":"Extended HF treatment<sup>b<\/sup>\/percutaneous edge-to-edge repair","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"998","boxType":BoxTypes.FOOTER,"hasFootnote":true,"referenceText":"<sup>a<\/sup>When there is a high likelihood of durable valve repair at a low-risk, valve repair should be considered (IIa C) in patients with LVESD ≥40 mm and one of the following is present: flail leaflet or LA volume ≥60 mL\/m² BSA at sinus rhythm -\n<sup>b<\/sup>Extended HF management includes the following: CRT; ventricular assist devices; cardiac restraint devices; heart transplantation.","hasAbbreviation":true,"abbreviationText":"AF = atrial fibrillation; BSA = body surface area; CRT = cardiac resynchronization therapy; HF = heart failure; LA = left atrial; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP = systolic pulmonary arterial pressure.","staticImageName":"interactive_0001435","extraButtons":[{"buttonRow":[{"text":"Abbreviation(s) and Footnote(s)","buttonId":FooterButtons.REF_BUTTON},{"image":"Flip PDF","buttonId":FooterButtons.PDF_BUTTON}]},{"buttonRow":[{"text":"Reset","buttonId":FooterButtons.RESET_BUTTON},{"text":"<a class='more-info-link' href='ref_ENAS5328_7.2.3.2.html'>More Information</a>","buttonId":FooterButtons.MORE_INFO_BUTTON}]}]}];